Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Australia to offer businesses $693 million in cheap loans to ease fuel cost pressure - 2People can't get enough of this couple's Hallmark movie reviews. They don't know the painful backstory.
- 3Pfizer in $41.5 million settlement with Texas over ADHD drug for children
- 4Iranian missile hit on Ne'ot Hovav factory leads to fear of chemical leakage
- 5When faith comes under fire: How Iran’s repression of religious minorities has increased
- Polar bears are rewiring their own genetics to survive a warming climate
- 6 Trail blazing Bicycles for Rough terrain Undertakings
- Tributes pour in for James Ransone, 'The Wire' actor who died at 46
- Indonesian Mega-Farm Drives Surge in Deforestation
- EU chief urges Iran to free imprisoned protesters, lift internet ban
- South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
- Tasting America: An Excursion Through Darling Cheap Food Brands
- New research reveals urban raccoons across the US show early signs of domestication
- Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
